Company Encyclopedia
View More
name
Junshi Biosciences
688180.SH
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of malignant tumors, neurological, autoimmune, chronic metabolic, nervous system, and infectious diseases in the People's Republic of China. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
1.601 T
688180.SHMarket value -Rank by Market Cap -/-

Financial Score

08/11/2025 Update
C
BiotechnologyIndustry
Industry Ranking18/79
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-15.33%E
    • Profit Margin-38.25%E
    • Gross Margin84.45%A
  • Growth ScoreB
    • Revenue YoY38.93%A
    • Net Profit YoY47.33%B
    • Total Assets YoY7.65%B
    • Net Assets YoY0.24%C
  • Cash ScoreC
    • Cash Flow Margin-261.41%D
    • OCF YoY38.93%A
  • Operating ScoreD
    • Turnover0.22D
  • Debt ScoreC
    • Gearing Ratio46.14%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    J.P. Morgan Remains a Sell on Shanghai Junshi Biosciences Co., Ltd. Class H (1877)

    According to TipRanks, Huang is a 5-star analyst with an average return of 36.9% and a 67.57% success rate. Huang covers the Healthcare sector, focusing on stocks such as Innovent Biologics, Wuxi Biologics (Cayman), and Hangzhou Tigermed Consulting Co., Ltd. Class H. The word on The Street in general, suggests a Hold analyst consensus rating for Shanghai Junshi Biosciences Co., Ltd. Class H with a HK$30.56 average price target.

    Tip Ranks·
    SH
    688180
    -1.92%
    HK
    01877
    -5.62%
    Tip Ranks·
    SH
    688180
    -1.92%
    HK
    01877
    -5.62%

    Zhitong Hong Kong Stock Short Position Statistics | October 31

    As of October 24, the three stocks with the highest short interest ratios in the Hong Kong stock market are ZTE Corporation (15.82%), CHINA VANKE (15.47%), and COSCO SHIP HOLD (15.42%). The stocks with the largest increases in short interest ratios are Junshi Biosciences-B, Sanhua Intelligent Controls, and Giant Biogene, which increased by 2.41%, 2.04%, and 1.06%, respectively. The stocks with the largest decreases in short interest ratios are JUNSHI BIO, MING YUAN CLOUD, and SD GOLD, which decreased by 0.95%, 0.94%, and 0.93%, respectively

    Zhitong·
    SH
    688180
    -1.92%
    HK
    01877
    -5.62%
    SZ
    000002
    0.00%
    Zhitong·
    SH
    688180
    -1.92%
    HK
    01877
    -5.62%
    SZ
    000002
    0.00%

    Hong Kong stocks in the innovative drug concept sector continue to strengthen, with RemeGen rising over 8%

    Hong Kong stocks related to innovative pharmaceuticals continue to strengthen, with RemeGen rising over 8%, INNOVENT BIO rising over 7%, and FOSUN PHARMA, JUNSHI BIO, and JOINN rising over 5%

    Zhitong·
    SH
    600196
    -0.91%
    HK
    02196
    -1.58%
    SH
    688180
    -1.92%
    Zhitong·
    SH
    600196
    -0.91%
    HK
    02196
    -1.58%
    SH
    688180
    -1.92%

    Understanding the Market | Junshi Biosciences rose over 4% as the net loss attributable to the parent company in the first three quarters narrowed by 35.7% year-on-year, with strong sales performance of Tuoyi®

    Junshi Biosciences rose over 4%, as of the time of writing, up 3.99%, priced at HKD 26.06, with a transaction volume of HKD 59.4286 million. In terms of news, on October 28th, Junshi Biosciences announced that for the first three quarters of 2025, operating revenue was RMB 1.806 billion, a year-on-year increase of 42.06%; the net loss attributable to shareholders of the listed company was RMB 596 million, a year-on-year narrowing of 35.7%; basic loss per share was RMB 0.60. The announcement stated that the growth in operating revenue during the period was mainly due to the increase in sales revenue from commercialized drugs, among which the core product Toripalimab injection (trade name: Tuoyi®/LOQTORZI®, product code: JS001) achieved sales revenue of approximately RMB 1.495 billion in the domestic market, a year-on-year increase of about 40%. At the same time, the company continues to implement the "Quality Improvement, Efficiency Enhancement, and Return Focus" action plan, strengthening expense control and resource focus, with the loss amount significantly narrowing compared to the same period last year. As of the end of the reporting period, the company's cash and cash equivalents and trading financial assets totaled RMB 3.270 billion, indicating a relatively sufficient capital reserve

    Zhitong·
    SH
    688180
    -1.92%
    HK
    01877
    -5.62%
    Zhitong·
    SH
    688180
    -1.92%
    HK
    01877
    -5.62%

    The Hong Kong stock biotechnology sector collectively weakened, with QYUNS-B and LEADS BIOLABS-B falling over 10%

    The Hong Kong stock biotechnology sector collectively weakened, with QYUNS-B and LEADS BIOLABS-B falling over 10%, while RemeGen, JUNSHI BIO, and WuXi BIO all declined

    Zhitong·
    SH
    688180
    -1.92%
    HK
    01877
    -5.62%
    US
    WXXWY
    -2.91%
    Zhitong·
    SH
    688180
    -1.92%
    HK
    01877
    -5.62%
    US
    WXXWY
    -2.91%